Sanofi Gains FDA Approval for Dupixent AFRS Indication and EU Opinion for Sleeping Sickness Drug
Sanofi receives FDA approval for Dupixent to treat allergic fungal rhinosinusitis and gains European endorsement for Acoziborole Winthrop as a sleeping sickness treatment, which will be donated to WHO.
Sanofi has received US FDA approval for Dupixent as the first treatment for allergic fungal rhinosinusitis (AFRS) in adults and children. The new AFRS indication broadens Dupixent's reach into another defined population of patients with type 2 inflammatory disease.
The European Medicines Agency has issued a positive opinion for Acoziborole Winthrop, developed with DNDi, as a treatment for sleeping sickness. Sanofi plans to donate Acoziborole Winthrop to the World Health Organization for use in tackling this rare and neglected tropical disease.
Dupixent's AFRS approval adds another clearly defined, high-need niche to an already broad respiratory and allergy franchise, which can deepen the product's reach rather than just relying on volume in existing indications. EU endorsement of Acoziborole Winthrop, paired with plans to donate it for sleeping sickness, reinforces Sanofi's global health profile and its ability to work with organizations like the WHO on complex access models.
The Dupixent new indication and CHMP opinion in pediatric CSU align with the narrative that Sanofi's future upside depends on pipeline delivery in high-value chronic diseases and continued execution in biologics. Relying heavily on Dupixent across many indications can still test the narrative's assumption of long term margin stability, as concentration in one medicine increases exposure to future competition and pricing pressure.
The breadth of Sanofi's portfolio, from Dupixent in chronic inflammatory disease to Acoziborole in sleeping sickness, may support a more diversified opportunity set than single-franchise biotech peers. Earnings are forecast to grow, with new approvals like AFRS helping underpin the revenue base.